Recent experimental data suggest that angiotensin-converting enzyme (ACE) inhibitors and AT1R antagonists have a suppressive effect on tumor progression through the normalization of the tumor vasculature, decreases in the deposition of the extracellular matrix, and the modulation of the tumor immune microenvironment [16,17,18]. This evidence concerns the gene AGTR1 and neoplasm.